Resources
28 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Join HRSA’s Bureau of Health Workforce regional team to learn more about NHSC as a provider recruitment and retention tool in rural communities.
Posted 10/7/2019 (updated 3/25/2024)
Meeting the Workforce Challenges of the Opioid Crisis in Rural America Webinar Presentation and Materials
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 10/17/2022 (updated 3/27/2024)
HRSA's Health Workforce Connector connects skilled health professionals to communities in need. With this resource, search thousands of employment and training opportunities in underserved communities across the nation, create a personal profile so recruiters can find you to fill open positions and access 24,000 + healthcare facilities located in rural and underserved communities.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 11/22/2022 (updated 3/27/2024)
Over its 36 year history, the Federal Office of Rural Health Policy has provided billions of dollars in funding to increase health care access, strengthen health networks, and focus on care quality improvements for Critical Access Hospitals and small rural hospitals. In fiscal year 2022, the Health Resources and Services Administration (HRSA) – through the Federal Office of Rural Health Policy (FORHP) – provided approximately $408 million in funding to increase health care access, strengthen health networks, and focus on care quality improvements for Critical Access Hospitals and small rural hospitals.
Posted 1/31/2023 (updated 3/27/2024)
Training Material